<DOC>
	<DOCNO>NCT00088530</DOCNO>
	<brief_summary>BBR 2778 novel aza-anthracenedione activity experimental tumor show reduce potential cardiotoxicity animal model . This cytotoxic agent structural similarity mitoxantrone well general similarity anthracyclines ( tricyclic central quinoid chromophore ) . The primary study objective compare efficacy BBR 2778 selection single agent . Secondary objective compare safety tolerability BBR 2778 selection single agent , assess pharmacokinetic parameter BBR 2778 subset patient population .</brief_summary>
	<brief_title>BBR 2778 Relapsed , Aggressive Non-Hodgkin 's Lymphoma ( NHL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Pixantrone</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Histologically confirm aggressive [ de novo transform ] NHL accord REAL/WHO classification . At least one objectively measurable lesion demonstrate CT , spiral CT , MRI plain radiograph chest ( chest xray , chest lesion ) follow response target lesion . Relapse 2 prior regimen chemotherapy ECOG performance status 0 , 1 , 2 Adequate hematologic , renal hepatic function LVEF ≥50 % determine MUGA scan Prior treatment cumulative dose doxorubicin equivalent exceed 450 mg/m² Prior allogenic stem cell transplant Histological diagnosis Burkitt lymphoma , lymphoblastic lymphoma Mantle cell lymphoma Active CNS lymphoma HIVrelated lymphoma . Any chemotherapy , radiotherapy , anticancer treatment ( include corticosteroid , 10 mg/day prednisone equivalent ) within 2 week randomization Pregnant woman nurse mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Pixantrone</keyword>
	<keyword>Non-Hodgkins lymphoma</keyword>
</DOC>